000258252 001__ 258252
000258252 005__ 20231004134646.0
000258252 0247_ $$2doi$$a10.3389/fneur.2023.1080752
000258252 0247_ $$2pmid$$apmid:37260606
000258252 0247_ $$2pmc$$apmc:PMC10228366
000258252 0247_ $$2altmetric$$aaltmetric:148411450
000258252 037__ $$aDZNE-2023-00598
000258252 041__ $$aEnglish
000258252 082__ $$a610
000258252 1001_ $$aAntonini, Angelo$$b0
000258252 245__ $$aToward objective monitoring of Parkinson's disease motor symptoms using a wearable device: wearability and performance evaluation of PDMonitor®.
000258252 260__ $$aLausanne$$bFrontiers Research Foundation$$c2023
000258252 3367_ $$2DRIVER$$aarticle
000258252 3367_ $$2DataCite$$aOutput Types/Journal article
000258252 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686817637_19488
000258252 3367_ $$2BibTeX$$aARTICLE
000258252 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258252 3367_ $$00$$2EndNote$$aJournal Article
000258252 520__ $$aParkinson's disease (PD) is characterized by a variety of motor and non-motor symptoms. As disease progresses, fluctuations in the response to levodopa treatment may develop, along with emergence of freezing of gait (FoG) and levodopa induced dyskinesia (LiD). The optimal management of the motor symptoms and their complications, depends, principally, on the consistent detection of their course, leading to improved treatment decisions. During the last few years, wearable devices have started to be used in the clinical practice for monitoring patients' PD-related motor symptoms, during their daily activities. This work describes the results of 2 multi-site clinical studies (PDNST001 and PDNST002) designed to validate the performance and the wearability of a new wearable monitoring device, the PDMonitor®, in the detection of PD-related motor symptoms. For the studies, 65 patients with Parkinson's disease and 28 healthy individuals (controls) were recruited. Specifically, during the Phase I of the first study, participants used the monitoring device for 2-6 h in a clinic while neurologists assessed the exhibited parkinsonian symptoms every half hour using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, as well as the Abnormal Involuntary Movement Scale (AIMS) for dyskinesia severity assessment. The goal of Phase I was data gathering. On the other hand, during the Phase II of the first study, as well as during the second study (PDNST002), day-to-day variability was evaluated, with patients in the former and with control subjects in the latter. In both cases, the device was used for a number of days, with the subjects being unsupervised and free to perform any kind of daily activities. The monitoring device produced estimations of the severity of the majority of PD-related motor symptoms and their fluctuations. Statistical analysis demonstrated that the accuracy in the detection of symptoms and the correlation between their severity and the expert evaluations were high. As a result, the studies confirmed the effectiveness of the system as a continuous telemonitoring solution, easy to be used to facilitate decision-making for the treatment of patients with Parkinson's disease.
000258252 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000258252 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000258252 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258252 650_7 $$2Other$$aParkinson's disease
000258252 650_7 $$2Other$$aautomatic ambulatory monitoring
000258252 650_7 $$2Other$$adigital health
000258252 650_7 $$2Other$$ainertial measurement unit sensors
000258252 650_7 $$2Other$$atelemonitoring
000258252 650_7 $$2Other$$awearable devices
000258252 7001_ $$aReichmann, Heinz$$b1
000258252 7001_ $$aGentile, Giovanni$$b2
000258252 7001_ $$aGaron, Michela$$b3
000258252 7001_ $$aTedesco, Chiara$$b4
000258252 7001_ $$0P:(DE-2719)9001473$$aFrank, Anika$$b5$$udzne
000258252 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Bjoern$$b6$$udzne
000258252 7001_ $$aKonitsiotis, Spyridon$$b7
000258252 7001_ $$aTsamis, Konstantinos$$b8
000258252 7001_ $$aRigas, Georgios$$b9
000258252 7001_ $$aKostikis, Nicholas$$b10
000258252 7001_ $$aNtanis, Adamantios$$b11
000258252 7001_ $$aPattichis, Constantinos$$b12
000258252 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2023.1080752$$gVol. 14, p. 1080752$$p1080752$$tFrontiers in neurology$$v14$$x1664-2295$$y2023
000258252 8564_ $$uhttps://www.frontiersin.org/articles/10.3389/fneur.2023.1080752/full
000258252 8564_ $$uhttps://pub.dzne.de/record/258252/files/DZNE-2023-00598.pdf$$yOpenAccess
000258252 8564_ $$uhttps://pub.dzne.de/record/258252/files/DZNE-2023-00598.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258252 909CO $$ooai:pub.dzne.de:258252$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000258252 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001473$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000258252 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000258252 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000258252 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000258252 9141_ $$y2023
000258252 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000258252 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000258252 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000258252 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000258252 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000258252 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000258252 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258252 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000258252 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:11:28Z
000258252 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000258252 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000258252 9201_ $$0I:(DE-2719)1710001$$kAG Kempermann 1 ; AG Kempermann$$lAdult Neurogenesis$$x0
000258252 9201_ $$0I:(DE-2719)1710012$$kClinical Study Team Dresden ; AG Falkenburger$$lClinical Study Team Dresden$$x1
000258252 980__ $$ajournal
000258252 980__ $$aVDB
000258252 980__ $$aUNRESTRICTED
000258252 980__ $$aI:(DE-2719)1710001
000258252 980__ $$aI:(DE-2719)1710012
000258252 9801_ $$aFullTexts